GlassScriptPhysician profile
Justin Lamar Smith
NPI 1982015590
$2,552.51
in general payments reported to CMS, 2019-2025
20 companies · $691 in 2025
The $691 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $272 · 2021: $152 · 2022: $197 · 2023: $479 · 2024: $569 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.80 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.88 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $344.02 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $300.88 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $252.84 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $223.88 | 2020-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $111.73 | 2021-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.14 | 2025 | Caplyta |
| Pfizer INC. | $78.30 | 2025 | |
| Abbott Laboratories | $65.42 | 2024-2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $63.34 | 2023-2024 | Accrufer |
| Cardiva Medical, INC. | $52.28 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Exact Sciences Corporation | $36.36 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $31.08 | 2022-2023 | Quviviq |
| Mylan Specialty L.P. | $21.22 | 2022 | |
| Sumitomo Pharma America, INC. | $18.94 | 2025 | Gemtesa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $18.70 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $18.44 | 2025 | Rexulti |
| Ferring Pharmaceuticals INC. | $17.42 | 2023 | Rebyota |
| Boston Scientific Corporation | $15.68 | 2024 | Wavewriter Alpha Prime 16 |
| Allergan, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.